Pay in 4 interest-free payments of $6.46 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
The emerging role of GLP-1 receptor agonists in alcohol use disorder: A review of preclinical and early clinical studies
RGN-352 was shown to be safe and well-tolerated with no serious drug-related adverse events reported (PMID: 20536472) Phase 2 AMI trial (incomplete): RegeneRx designed a Phase 2 proof-of-concept trial (NCT01311518) to evaluate RGN-352 in approximately 75 patients with acute ST-segment elevation myocardial infarction (heart attack)
Standard pre-treatment bloodwork includes comprehensive metabolic panel to check kidney and liver function, lipid panel for cholesterol, A1C or fasting glucose for diabetes screening, and thyroid panel
A with a that says "Peptide Dosage Calculator" is a much stronger signal than a
Consistent data collection makes protocol adjustments more informed and outcomes more meaningful
